Product Information

HYDROXYZINE PAM 25 MG CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.0627 per EA under NDC 00555032302. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Jun 15, 1984. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Hydroxyzine Pamoate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for HYDROXYZINE PAM 25 MG CAP has been published 665 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.